BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

623 related articles for article (PubMed ID: 28533196)

  • 21. Allogeneic hematopoietic stem cell transplantation for heavily pretreated patients with mycosis fungoides and Sezary syndrome.
    Cengiz Seval G; Sahin U; Bozdag SC; Yuksel MK; Topcuoglu P; Akay BN; Sanlı HE; Gurman G; Toprak SK; Ozcan M
    Dermatol Ther; 2022 May; 35(5):e15447. PubMed ID: 35289037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcome of allogeneic hematopoietic stem cell transplantation for mycosis fungoides and Sézary syndrome.
    Mori T; Shiratori S; Suzumiya J; Kurokawa M; Shindo M; Naoyuki U; Katsuto T; Miyamoto T; Morishige S; Hirokawa M; Fukuda T; Atsuta Y; Suzuki R
    Hematol Oncol; 2020 Aug; 38(3):266-271. PubMed ID: 32011008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Survival, disease progression and prognostic factors in elderly patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of 174 patients.
    Lebowitz E; Geller S; Flores E; Pulitzer M; Horwitz S; Moskowitz A; Kheterpal M; Myskowski PL
    J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):108-114. PubMed ID: 30176169
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.
    Kim YH; Liu HL; Mraz-Gernhard S; Varghese A; Hoppe RT
    Arch Dermatol; 2003 Jul; 139(7):857-66. PubMed ID: 12873880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circulating CD4+CD7- lymphocyte burden and rapidity of response: predictors of outcome in the treatment of Sézary syndrome and erythrodermic mycosis fungoides with extracorporeal photopheresis.
    Stevens SR; Baron ED; Masten S; Cooper KD
    Arch Dermatol; 2002 Oct; 138(10):1347-50. PubMed ID: 12374541
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and Histological Characteristics of Mycosis Fungoides and Sézary Syndrome: A Retrospective, Single-centre Study of 43 Patients from Eastern Denmark.
    Nielsen PR; Eriksen JO; Wehkamp U; Lindahl LM; Gniadecki R; Fogh H; Fabricius S; Bzorek M; Ødum N; Gjerdrum LM
    Acta Derm Venereol; 2019 Dec; 99(13):1231-1236. PubMed ID: 31620804
    [TBL] [Abstract][Full Text] [Related]  

  • 27. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017.
    Trautinger F; Eder J; Assaf C; Bagot M; Cozzio A; Dummer R; Gniadecki R; Klemke CD; Ortiz-Romero PL; Papadavid E; Pimpinelli N; Quaglino P; Ranki A; Scarisbrick J; Stadler R; Väkevä L; Vermeer MH; Whittaker S; Willemze R; Knobler R
    Eur J Cancer; 2017 May; 77():57-74. PubMed ID: 28365528
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management experience of advanced-stage mycosis fungoides/Sézary syndrome: a retrospective study from Spanish haematology referral units.
    Novelli S; Martín A; Sánchez JJ; Espeso M; Mozos A; Briones J
    Eur J Dermatol; 2020 Aug; 30(4):397-403. PubMed ID: 32815814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and Sézary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.
    Domingo-Domenech E; Duarte RF; Boumedil A; Onida F; Gabriel I; Finel H; Arcese W; Browne P; Beelen D; Kobbe G; Veelken H; Arranz R; Greinix H; Lenhoff S; Poiré X; Ribera JM; Thompson J; Zuckerman T; Mufti GJ; Cortelezzi A; Olavarria E; Dreger P; Sureda A; Montoto S
    Bone Marrow Transplant; 2021 Jun; 56(6):1391-1401. PubMed ID: 33420392
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Retrospective Analysis of Prognostic Factors in 187 Cases of Transformed Mycosis Fungoides.
    Talpur R; Sui D; Gangar P; Dabaja BS; Duvic M
    Clin Lymphoma Myeloma Leuk; 2016 Jan; 16(1):49-56. PubMed ID: 26702474
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mycosis fungoides and Sézary syndrome: Current challenges in assessment, management and prognostic markers.
    Hughes CF; Newland K; McCormack C; Lade S; Prince HM
    Australas J Dermatol; 2016 Aug; 57(3):182-91. PubMed ID: 25988337
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mycosis fungoides and sezary syndrome: an update.
    Kim EJ; Lin J; Junkins-Hopkins JM; Vittorio CC; Rook AH
    Curr Oncol Rep; 2006 Sep; 8(5):376-86. PubMed ID: 16901399
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome.
    Duvic M; Donato M; Dabaja B; Richmond H; Singh L; Wei W; Acholonu S; Khouri I; Champlin R; Hosing C
    J Clin Oncol; 2010 May; 28(14):2365-72. PubMed ID: 20351328
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mycosis fungoides and Sézary syndrome.
    Jonak C; Tittes J; Brunner PM; Guenova E
    J Dtsch Dermatol Ges; 2021 Sep; 19(9):1307-1334. PubMed ID: 34541796
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Annual Facility Treatment Volume and Patient Survival for Mycosis Fungoides and Sézary Syndrome.
    Kann BH; Park HS; Yeboa DN; Aneja S; Girardi M; Foss FM; Roberts KB; Wilson LD
    Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):520-526.e2. PubMed ID: 28655598
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hematopoietic stem cell transplantation in advanced cutaneous T-cell lymphoma.
    Saruta H; Ohata C; Muto I; Imamura T; Oku E; Ohshima K; Nagafuji K; Nakama T
    J Dermatol; 2017 Sep; 44(9):1038-1042. PubMed ID: 28391645
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determination of immunophenotypic aberrancies provides better assessment of peripheral blood involvement by mycosis fungoides/Sézary syndrome than quantification of CD26- or CD7- CD4+ T-cells.
    Lyapichev KA; Bah I; Huen A; Duvic M; Routbort MJ; Wang W; Jorgensen JL; Medeiros LJ; Vega F; Craig FE; Wang SA
    Cytometry B Clin Cytom; 2021 Mar; 100(2):183-191. PubMed ID: 32667737
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Presentation and Outcome Differences Between Black Patients and Patients of Other Races and Ethnicities With Mycosis Fungoides and Sézary Syndrome.
    Allen PB; Goyal S; Niyogusaba T; O'Leary C; Ayers A; Tarabadkar ES; Khan MK; Lechowicz MJ
    JAMA Dermatol; 2022 Nov; 158(11):1293-1299. PubMed ID: 36069854
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic factor analysis in mycosis fungoides/Sézary syndrome.
    Diamandidou E; Colome M; Fayad L; Duvic M; Kurzrock R
    J Am Acad Dermatol; 1999 Jun; 40(6 Pt 1):914-24. PubMed ID: 10365922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.